HUP0400657A1 - Fibroblast growth factors - Google Patents

Fibroblast growth factors

Info

Publication number
HUP0400657A1
HUP0400657A1 HU0400657A HUP0400657A HUP0400657A1 HU P0400657 A1 HUP0400657 A1 HU P0400657A1 HU 0400657 A HU0400657 A HU 0400657A HU P0400657 A HUP0400657 A HU P0400657A HU P0400657 A1 HUP0400657 A1 HU P0400657A1
Authority
HU
Hungary
Prior art keywords
growth factors
fibroblast growth
fibroblast
factors
growth
Prior art date
Application number
HU0400657A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter W Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HUP0400657A1 publication Critical patent/HUP0400657A1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400657A 2000-12-08 2001-12-10 Fibroblast growth factors HUP0400657A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
HUP0400657A1 true HUP0400657A1 (en) 2006-04-28

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400657A HUP0400657A1 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (enExample)
EP (1) EP1389237A2 (enExample)
JP (1) JP2005506275A (enExample)
KR (1) KR20040052442A (enExample)
CN (1) CN1518597A (enExample)
AU (1) AU2603402A (enExample)
BG (1) BG107888A (enExample)
BR (1) BR0116507A (enExample)
CA (1) CA2431374A1 (enExample)
CZ (1) CZ20031570A3 (enExample)
EE (1) EE200300269A (enExample)
HU (1) HUP0400657A1 (enExample)
IL (1) IL156259A0 (enExample)
MX (1) MXPA03005142A (enExample)
NO (1) NO20032573L (enExample)
PL (1) PL366158A1 (enExample)
RU (1) RU2329058C2 (enExample)
SI (1) SI21372A (enExample)
SK (1) SK7012003A3 (enExample)
WO (1) WO2002046424A2 (enExample)
ZA (1) ZA200305236B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
WO2004090112A2 (en) 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
PT1232264E (pt) * 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
AU2603402A (en) 2002-06-18
WO2002046424A2 (en) 2002-06-13
EP1389237A2 (en) 2004-02-18
SI21372A (sl) 2004-06-30
AU2002226034A2 (en) 2002-06-18
CZ20031570A3 (cs) 2004-01-14
ZA200305236B (en) 2005-06-29
CA2431374A1 (en) 2002-06-13
MXPA03005142A (es) 2004-10-15
RU2003119657A (ru) 2005-02-27
KR20040052442A (ko) 2004-06-23
EE200300269A (et) 2003-10-15
US20080057076A1 (en) 2008-03-06
PL366158A1 (en) 2005-01-24
NO20032573L (no) 2003-07-22
NO20032573D0 (no) 2003-06-06
IL156259A0 (en) 2004-01-04
US20020151496A1 (en) 2002-10-17
BR0116507A (pt) 2004-01-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
WO2002046424A3 (en) 2003-11-27
BG107888A (bg) 2004-08-31
SK7012003A3 (en) 2004-04-06

Similar Documents

Publication Publication Date Title
CA95984S (en) Pantiliner
IL156259A0 (en) Novel fibroblast growth factors
AU3924300A (en) Fibroblast growth factor-20
AUPR030900A0 (en) Growth factor complex
IL151010A0 (en) Linezolid-crystal form ii
DE50110354D1 (en) Achsantriebsblock mit differentialsperre
GB0112854D0 (en) Object particularly implant
GB0007451D0 (en) Tableware
CA90931S (en) Pantiliner
AU9149301A (en) Growth factor complex
GB0013272D0 (en) Neurotropic growth factor
GB0000829D0 (en) Growth inhibitor
CA90930S (en) Pantiliner
PL110493U1 (en) Frog
TW418600U (en) Convex flowerpot
AU143581S (en) Pantiliner
TW425839U (en) Flowerpot
PL110774U1 (en) Flowerpot
EG22820A (en) Bio-geometrical shapes
GB0009389D0 (en) Ward off
DE60130116D1 (en) Modularer applikator zur reflexotherapie
EG22115A (en) Greenhouse
CA86570S (en) Greenhouse
TW414240U (en) Tent-roof improvement
IL133873A0 (en) Improved prosthesis

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees